Theraclion notifies availability of H1 2026 progress press release

  • Theraclion released a first-half 2026 business update, citing early commercial traction for its Sonovein varicose vein HIFU platform.
  • Signed seven new pay-per-use contracts. Four systems installed by June 30.
  • US reimbursement path advanced with a Category III CPT code effective Jan. 1, 2027. FDA De Novo decision expected late Q3 to early Q4 2026.
  • First-half revenue fell 21% to EUR 663,000. PPU revenue rose 9% to EUR 333,000.
  • Cash was EUR 5.2 million at June 30. Runway expected into Q1 or Q2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theraclion SA published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.